The estimated Net Worth of Pte Ltd.Pillai Arun Kumar S... is at least $358 Million dollars as of 19 March 2020. Pte S owns over 29,358,621 units of Outlook Therapeutics Inc stock worth over $358,284,358 and over the last 7 years Pte sold OTLK stock worth over $0.
Pte has made over 4 trades of the Outlook Therapeutics Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently Pte exercised 29,358,621 units of OTLK stock worth $206,391,106 on 19 March 2020.
The largest trade Pte's ever made was exercising 29,358,621 units of Outlook Therapeutics Inc stock on 19 March 2020 worth over $206,391,106. On average, Pte trades about 3,555,217 units every 25 days since 2017. As of 19 March 2020 Pte still owns at least 50,965,058 units of Outlook Therapeutics Inc stock.
You can see the complete history of Pte S stock trades at the bottom of the page.
Over the last 6 years, insiders at Outlook Therapeutics Inc have traded over $1,453,842 worth of Outlook Therapeutics Inc stock and bought 29,698,365 units worth $33,411,235 . The most active insiders traders include Pte Ltd.Pillai Arun Kumar S..., Ghiath M.Gms Ventures & Inv..., and Ventures Llc Syntone. On average, Outlook Therapeutics Inc executives and independent directors trade stock every 43 days with the average trade being worth of $11,985,869. The most recent stock trade was executed by Ventures Llc Syntone on 15 April 2024, trading 714,286 units of OTLK stock currently worth $5,021,431.
overview oncobiologics is a pure-play complex biosimilar company focused on technically challenging and commercially attractive monoclonal antibodies (mabs), in the therapeutic areas of immunology and oncology. our strategy is to cost-effectively develop technically challenging biosimilars on an accelerated timeline, which we believe is fundamental to our success and positions us to be a leading biosimilar company. we have leveraged our team’s biopharmaceutical expertise to establish fully integrated in-house development and manufacturing capabilities, which we refer to as our biosymphony™ platform. oncobiologics’ platform addresses the numerous complex technical and regulatory challenges in developing and commercializing mab biosimilars. pipeline oncobiologics is actively working on eight biosimilar candidates. the company’s most advanced assets, ons-3010 (a biosimilar of humira®) and ons-1045 (a biosimilar of avastin®) have both successfully completed phase i trials and phase 3 t
Outlook Therapeutics Inc executives and other stock owners filed with the SEC include: